The estimated Net Worth of Helen Katrina Tayton Martin is at least $5.5 Million dollars as of 3 March 2021. Helen Martin owns over 1,785,000 units of Adaptimmune Therapeutics Plc stock worth over $1,944,000 and over the last 9 years he sold ADAP stock worth over $2,198,000. In addition, he makes $1,355,090 as Chief Business Officer at Adaptimmune Therapeutics Plc.
Helen has made over 3 trades of the Adaptimmune Therapeutics Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,785,000 units of ADAP stock worth $285,600 on 3 March 2021.
The largest trade he's ever made was exercising 1,785,000 units of Adaptimmune Therapeutics Plc stock on 3 March 2021 worth over $285,600. On average, Helen trades about 173,750 units every 35 days since 2016. As of 3 March 2021 he still owns at least 1,800,000 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Helen Martin stock trades at the bottom of the page.
Dr. Helen Katrina Tayton-Martin Ph.D. serves as Chief Business Officer of the Company. She was Chief Operating Officer of the Company. Dr. Tayton-Martin has 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She formerly served as Chief Operating Officer and is a co-founder of Adaptimmune, joining from Avidex Limited (subsequently Medigene) where she was responsible for commercial development of the soluble TCR program in cancer and HIV therapy. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.
As the Chief Business Officer of Adaptimmune Therapeutics Plc, the total compensation of Helen Martin at Adaptimmune Therapeutics Plc is $1,355,090. There are 3 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of $2,821,740.
Helen Martin is 53, he's been the Chief Business Officer of Adaptimmune Therapeutics Plc since 2017. There are 13 older and 6 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
Helen's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include: